New authorizations to resume patient enrollment in Phase 3 studies of masitinib
14/09/2021 – AB Science announced that it has received new authorizations to resume patient enrollment in its Phase 3 studies of masitinib
Results from masitinib study AB12003 in prostate cancer have been presented at the 2021 American Urological Association
13/09/2021 – AB Science today announced that results from masitinib study AB12003 in metastatic castrate refractory prostate cancer, have been presented as a podium presentation at the 2021 American Urological Association
Latest clinical data on long-term survival analyses in ALS will be presented at the 2021 symposium on ALS/MND
02/09/2021 – AB Science announced today that latest clinical data on long-term survival analyses in ALS will be presented at the 2021 symposium on ALS/MND
Second authorization to resume patient enrollment, in the Phase 3 study of masitinib in mastocytosis
25/08/2021 – AB Science announced today that it has received authorization from the French National Agency (ANSM) to resume patient enrollment in the confirmatory Phase 3 study of masitinib (AB15003) in mastocytosis
First authorization to resume patient enrollment in the Phase 3 study of masitinib in ALS
23/08/2021 – AB Science today announced that it has received the first authorization to resume patient enrollment in the confirmatory Phase 3 study of masitinib (AB19001) in amyotrophic lateral sclerosis (ALS)
Publication of a pathogenic mechanism triggered by mast cells in the ALS spinal cord that can be targeted by masitinib
19/08/2021 – AB Science announced the publication of a pathogenic mechanism triggered by mast cells in the amyotrophic lateral sclerosis (ALS) spinal cord that can be targeted by masitinib
Q&A press release following-up on the June 28, 2021 press release relating to an agreement with historical shareholders
06/08/2021 – AB Science publishes a Q&A press release, following-up on its June 28, 2021 press release relating to an agreement with historical shareholders
Results from Phase 3 AB09004 study on Alzheimer’s disease have been presented at the annual Alzheimer’s Association International Conference (AAIC)
29/07/2021 – AB Science announced that results from its Phase 3 AB09004 study on mild to moderate Alzheimer’s disease have been presented at the annual Alzheimer’s Association International Conference (AAIC)
Presentation of results from Phase 3 AB09004 study on Alzheimer’s disease at the annual Alzheimer’s Association International Conference (AAIC)
22/07/2021 – AB Science today announced that an abstract reporting results from its Phase 3 AB09004 study on Alzheimer’s disease has been selected for an oral presentation at the annual Alzheimer’s Association International Conference (AAIC)
Publication in the world-renowned journal Science confirms potential of masitinib as a treatment of Covid-19 with anti-viral activity against SARS-CoV-2 and all tested variants of concern
20/07/2021 – AB Science announces the publication of an article in the world-renowned journal Science that confirms potential of masitinib as a treatment of Covid-19 with anti-viral activity against SARS-CoV-2 and all tested variants of concern